Abstract
Systemic thromboxane generation, not suppressible by standard aspirin therapy and likely arising from nonplatelet sources, increases the risk of atherothrombosis and death in patients with cardiovascular disease. In the RIGOR (Reduction in Graft Occlusion Rates) study, greater nonplatelet thromboxane generation occurred early compared with late after coronary artery bypass graft surgery, although only the latter correlated with graft failure. We hypothesize that a similar differential association exists between nonplatelet thromboxane generation and long-term clinical outcome. Five-year outcome data were analyzed for 290 RIGOR subjects taking aspirin with suppressed platelet thromboxane generation. Multivariable modeling was performed to define the relative predictive value of the urine thromboxane metabolite, 11-dehydrothromboxane B2 (11-dhTXB2), measured 3 days versus 6 months after surgery on the composite end point of death, myocardial infarction, revascularization or stroke, and death alone. 11-dhTXB2 measured 3 days after surgery did not independently predict outcome, whereas 11-dhTXB2 >450 pg/mg creatinine measured 6 months after surgery predicted the composite end point (adjusted hazard ratio, 1.79; P=0.02) and death (a...Continue Reading
References
Jul 2, 1998·Clinical and Experimental Immunology·T IshizukaH Nakamura
Jul 21, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·P S PenglisM J James
Apr 10, 2002·Circulation·John W EikelboomSalim Yusuf
Nov 1, 2003·Thrombosis Research·Paola Patrignani
Dec 20, 2005·Journal of Thrombosis and Haemostasis : JTH·F M PulcinelliF Violi
Sep 5, 2006·The American Journal of Cardiology·Nauder FaradayLewis C Becker
Dec 21, 2006·Nature Clinical Practice. Cardiovascular Medicine·Carlo Patrono, Bianca Rocca
Jul 3, 2007·Journal of the American College of Cardiology·G Michael FelkerUNKNOWN CHARM Investigators
Jan 4, 2008·Circulation·Marcello TonelliUNKNOWN for the Cholesterol and Recurrent Events (CARE) Trial Investigators
Jan 5, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Carlo Patrono, Bianca Rocca
Oct 8, 2008·Circulation·John W EikelboomUNKNOWN Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators
Feb 24, 2009·Journal of the American College of Cardiology·Francesca SantilliCarlo Patrono
Jun 9, 2009·Thrombosis Research·Susanna M NazarianJeffrey J Rade
Jun 26, 2009·Journal of Thrombosis and Haemostasis : JTH·T J GluckmanJ J Rade
Feb 26, 2011·Journal of the American College of Cardiology·Tyler J GluckmanJeffrey J Rade
Apr 24, 2012·Thrombosis Research·Paul R J AmesLuis R Lopez
Jun 28, 2012·Pharmacogenetics and Genomics·Chung-Ying K ChenLee-Ho Wang
Oct 18, 2012·Journal of Thrombosis and Haemostasis : JTH·M T OlsonJ J Rade
Feb 13, 2013·Immunology·Johannes J KovarikGerhard J Zlabinger
Dec 5, 2013·Journal of Thrombosis and Haemostasis : JTH·V CapraK S Sakariassen
Apr 5, 2014·Vascular Pharmacology·Serena Del TurcoRaffaele De Caterina
May 27, 2014·Vascular Pharmacology·Michael Bode, Nigel Mackman
Jun 20, 2014·Journal of Thrombosis and Haemostasis : JTH·P PatrignaniA Lanas
Mar 17, 2016·Journal of Translational Medicine·Nóra HomoródiLászló Muszbek
Apr 14, 2016·Journal of the American Heart Association·Nikolaos KakourosJeffrey J Rade
Aug 3, 2016·Journal of the American Heart Association·Wojciech SzczeklikMarek Sanak
Nov 7, 2016·Thrombosis Research·Peter A McCulloughTeodoro Bottiglieri
Nov 10, 2016·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Sadeer G Al-KindiDavid A Zidar
Feb 1, 2017·The American Journal of Cardiology·Peter A McCulloughTeodoro Bottiglieri